Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

16 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-02

Study Completion Date

2021-12-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observational study to perform Whole Genome Sequencing in participants clinically suspected for HPP and negative for known pathogenic ALPL variants

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypophosphatasia (HPP) is a rare Inborn Error of Metabolism (IEM), characterized by low tissue-nonspecific isoenzyme of alkaline phosphatase (ALP) activity. Alkaline phosphatase (ALP) is crucial for osteoid mineralization. Its main substrate in bone is pyrophosphate (PPi), a natural inhibitor of mineralization. ALP cleaves pyrophosphate into its two phosphate moieties, which then become available to the mineralization process. This ALP deficiency results in accumulation of its substrates, mainly inorganic pyrophosphate (PPi), pyridoxal-5-phosphate (PLP), and phosphoethanolamine (PEA).

Beyond the bone and the Central Nervous System (CNS), ALP deficiency has an impact on a number of other organs and systems, resulting in a broad range of manifestations, including dental (premature tooth loss), muscular (muscle weakness, delayed walking, abnormal gait), rheumatic (calcium pyrophosphate deposition disease, fibromyalgia, fatigue, joint laxity), eye (calcifications), renal (nephrocalcinosis, kidney stones, renal failure), and gastrointestinal tract disturbance (gastroesophageal reflux).

The specific symptoms can vary greatly from one person to another, sometimes even among members of the same family. There are five major clinical forms of HPP (perinatal, infantile, childhood, adult, and odontohypophosphatasia), ranging from an extremely severe form that can cause stillbirth to a form associated with only premature loss of baby (deciduous) teeth, but no bone abnormalities.

The genetic reason of Hypophosphatasia is mainly caused by mutations in the ALPL gene, coding for the tissue nonspecific alkaline phosphatase isoenzyme. At least 397 distinct pathogenic variants (predominantly missense variants) were described to lead to low levels of the ALP enzyme. HPP can be inherited in an autosomal recessive (most perinatal and infantile forms) or autosomal dominant manner (typically the adult form and odontohypophosphatasia).

Since ALPL dependent prevalence is very low, while symptoms overlapping HPP are much more common, other primary - genetic - forms of HPP-like symptoms are to be sought and characterized.

The HPP genetics study aims to characterize the genetic background of HPP participants, who do not have pathogenic variant/s in the ALPL gene.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypophosphatasia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Hypophosphatasia HPP non-ALPL

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent is obtained from the participant or from the parent / legal guardian
* The participant is clinically suspected for HPP
* The participant does not have pathogenic variant/s in the ALPL gene
* The participant showed low alkaline phosphatase levels (age- and sex-adjusted) on at least two occasions at least a month apart based on the local laboratory reference range
* None of these conditions are present:

* Celiac disease and
* Clofibrate therapy and
* Cleidocranial dysplasia and
* Cushing's syndrome and
* Hypothyroidism and
* Massive Blood transfusion and
* Milk-alkali syndrome and
* Multiple myeloma and
* Osteogenesis imperfecta, type II and
* Pernicious or profound anemia and
* Starvation and
* Vitamin C deficiency and
* Vitamin D intoxication and
* Zinc deficiency and
* Magnesium deficiency

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter Bauer, Prof. Dr.

Role: STUDY_CHAIR

CENTOGENE GmbH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universität Würzburg - Klinische Studieneinheit, Orthopädische Klinik

Würzburg, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Seefried L, Petryk A, Del Angel G, Reder F, Bauer P. Whole genome sequencing in adults with clinical hallmarks of hypophosphatasia negative for ALPL variants. Mol Biol Rep. 2024 Sep 14;51(1):984. doi: 10.1007/s11033-024-09906-7.

Reference Type DERIVED

PMID: 39276275 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HPP genetics-2020

Identifier Type: -

Identifier Source: org_study_id